Migraine - Pipeline Review, H1 2017 report provides comprehensive information on the therapeutics
under development for Migraine, complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers
the descriptive pharmacological action of the therapeutics, its complete research and development
history and latest news and press releases. Additionally, the report provides an overview of key
players involved in therapeutic development for Migraine and features dormant and discontinued
projects.
Inquire for Complete Migraine Pipeline Review H1 2017 Report at
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1010754
Description of Report:
Migraine Pipeline Review H1 2017 report is built using data and information sourced from
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings,
investor presentations and featured press releases from company/university sites and industry-
specific third party sources. Drug profiles featured in the report undergoes periodic review following
a stringent set of processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis. The report helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision making capabilities and helps
to create effective counter strategies to gain competitive advantage.
Key Companies Analyzed In Report: 4P Therapeutics LLC, Achelios Therapeutics, Acorda
Therapeutics, Alder Biopharmaceuticals, Allergan Plc, Amgen, Aralez Pharmaceuticals, Astellas
Pharma, Avanir Pharmaceuticals, Biofrontera AG, BioHealthonomics, Charleston Laboratories,
Corium International, Eli Lilly and Company, Impel NeuroPharma, InKemia IUCT Group SA, InStar
Technologies AS, Ionis Pharmaceuticals, Klaria Pharma Holding AB, Medestea Research & Production
SpA, Merck & Co, Monosol Rx LLC, NAL Pharmaceuticals Ltd, Promius Pharma LLC, RedHill
Biopharma Ltd, Revance Therapeutics, Shin Nippon Biomedical Laboratories Ltd, Suda Ltd, Teva
Pharmaceutical Industries Ltd, TheraJect, Tonix Pharmaceuticals Holding Corp, Trevena, Trigemina,
TrioxBio, Vertex Pharmaceuticals, Xenon Pharmaceuticals, Zosano Pharma Corp.
Get Discount on Report at
http://www.reportsnreports.com/contacts/discount.aspx?name=1010754 (This report is
available at up to 25% Discount till June 02 nd 2017)
Scope: The report provides a snapshot of the global therapeutic landscape of Migraine. The report
reviews pipeline therapeutics for Migraine by companies and universities/research institutes based
on information derived from company and industry-specific sources. The report covers pipeline
products based on various stages of development ranging from pre-registration till discovery and
undisclosed stages. The report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other
developmental activities. The report reviews key players involved Migraine therapeutics and enlists
all their major and minor projects. The report assesses Migraine therapeutics based on drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The report